U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitroso-dabigatran (NDAB) Impurity
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitroso-dabigatran (NDAB) Impurity

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Recall Reason Description
Detection of N-nitroso-dabigatran (NDAB) Impurity
Company Name:
Ascend Laboratories LLC.
Brand Name:
Brand Name(s)
Ascend Laboratories
Product Description:
Product Description
Dabigatran Etexilate Capsules, USP

Company Announcement

FOR IMMEDIATE RELEASE- Parsippany. New Jersey. Ascend Laboratories LLC. is voluntarily recalling Dabigatran Etcxilate Capsules. USP 75 mg and 150 mg to the consumer/user level due to the presence of a nitrosamine. N-nitroso-dabigatran, above the established Acceptable Daily Intake (ADI) level. To date, Ascend Laboratories LLC., has not received any reports of adverse events related to this recall.

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.

The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.

The NDC. Lot Number. Expiration Date. and Packaging Configuration details for Dabigatran Etexilate Capsules that are subjected to this recall are indicated in the table belov,:. The product lots were distributed nationwide to wholesalers, Distributors and Retailers (dispensers) in the United States from June 2022 to October 2022.

Product NDC Lot
Number
Expiration
Date
Presentation Configuration
/Count
Dabigatran Etexilate
Mesylate Caps 150
Mg
67877-475-60 22142448 MAY.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 150
Mg
67877-475-60 22142449 MAY.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 150
Mg
67877-475-60 22142450 MAY.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 75 Mg
67877-474-60 22142462 MAY.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 75 Mg
67877-474-60 22142463 MAY.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 75 Mg
67877-474-60 22142464 MAY.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 75 Mg
67877-474-60 22143000 JUN.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 75 Mg
67877-474-60 22143001 JUN.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 75 Mg
67877-474-60 22143002 JUN.2024 HDPE
Bottles
60
capsules/bottle
Dabigatran Etexilate
Mesylate Caps 150
Mg
67877-475-60 22143845 JUL.2024 HDPE
Bottles
60
capsules/bottle

Wholesalers/distributors and pharmacies with an existing inventory of the lots listed in the table above, should stop use and distribution and quarantine the product immediately.

Wholesalers and Distributors are advised to recall the distributed product. Please notify any accounts or additional locations that may have received the recalled product from you. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Ascend requests that they immediately cease distribution of the affected product.

Patients who have received impacted lots of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg are advised to continue taking their medication and contact their physician for advice regarding an alternative treatment.

Consumers with questions regarding this recall can contact Ascend Laboratories LLC. using the below information.

Contact Center Contact Information Area of Support
Ascend Laboratories, LLC 877-272-7901, 24 hrs., 7 days a week To report adverse events and
product complaints

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Customers with medical-related questions, who wish to report an adverse event, or quality issues about the products being recalled should contact Ascend Laboratories LLC., by phone at: 877- 272-7901, 24 hrs., 7 days a week.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

 


Company Contact Information

Consumers:
Ascend Laboratories LLC.
877- 272-7901
Back to Top